Proactive: TruTrace Technologies working with Riviera & West One Logistics to launch sanitizer products

TruTrace Technologies (CSE:TTT) (OTCQB:TTTSF) CEO Robert Galarza tells Proactive the developer of a fully-integrated blockchain platform for the legal cannabis, food and pharmaceutical industries has said it is teaming up with Riviera & West One Logistics to ensure the highest quality for its line of products including Hygen-X hand and surface sanitizer products. Galarza says TruTrace’s launch with the company will mark the first implementation of its proprietary TruTrace Enterprise SaaS platform in sectors outside of the medical cannabis sector.

New Cannabis Ventures: Organigram Partners with Shoppers in Medical Cannabis Pilot Program

Organigram Joins Medical Cannabis by Shoppers Inc. and TruTrace in Effort to Track Source and Genetics of Cannabis Used by Medical Patients.

Project aims to match therapeutic outcomes to specific cannabis profiles and ensure consistent product for patients and healthcare practitioners…

Using Trutrace’s StrainSecure™ system, the program collects plant testing data and performs genomic verification in plant batches which are then registered in a blockchain-enabled database for intellectual property protection and strain validation. All information gathered from the plants, including their molecular and chemical makeup, can be tracked via the technology…

In the absence of assigned drug identification numbers (DIN) for cannabis products, quantifying the genetics and metabolomics, as well as potency and equivalencies of cannabis products is of interest to producers, distributors, shippers, government agencies, payers, clinicians and patients.

“Maintaining an effective traceability ecosystem about these details throughout the supply chain is a component of providing consistent medicine,” says Engel.

Using TruTrace technology, Shoppers has partnered with University Health Network in Toronto (UHN) to launch ‘Medical Cannabis Real World Evidence’ (MCRWE), a new ground-breaking study on cannabis and health which will track outcomes with TruTrace validated product for the first time in history.

This novel observational study is targeting a minimum of 2,000 patients who will be followed over a 24-week period.  Enrolled patients will have access to certain fully verified products on the Medical Cannabis by Shoppers platform, which have been tested for detailed cannabinoid and terpene profiles.  More information about the study can be found here.

Business Insider: Canada’s largest drugstore chain is partnering with a tech company to create an online database to track cannabis quality

“There is a stigma around recommending cannabis to patients in Canada. While medical cannabis has been legal in Canada for 19 years, doctors still feel uncertain authorizing its use to patients. 

Shoppers Drug Mart, Canada’s largest drugstore chain, is partnering with product quality and verification testing company TruTrace to create an online database to track cannabis quality.

The goal is to collect data on cannabis products from seed to sale, including a detailed chemistry and genetics of the plant and its metabolomic signatures, to understand what types help which patients.

“There was this idea that it was going to fix everything from Parkinson’s to Alzheimer’s to osteoarthritis to multiple sclerosis, but where’s the evidence?” said Dr. Hance Clark, who’s been working with Shoppers for the past four years. “The answer is, there isn’t much. It’s all anecdotal. So then the question is, how could we do this better, how could we change the system?”…

Shoppers Drug Mart, Canada’s largest drugstore chain, is attempting to mitigate confusing guidelines and information around cannabis use with a new partnership with the California based TruTrace, which does product quality and verification testing. The two are creating a new online portal, called Medical Cannabis By Shoppers Drug Mart, accessible to both patients and doctors that will track exactly what strains of flower, how many milligrams of THC, and what kinds of chemicals are in the products…”

Blockchain and pharmacies: How technology can make selling medical cannabis safer

By Robert Galarza

Many patients swear by medical cannabis as an effective treatment for a wide swathe of ailments and symptoms, including chronic pain, opioid dependency, nausea, sleep disturbances, and anxiety.

As a result of the regulatory changes that occurred when cannabis was federally legalized in October 2018, patients can now purchase their cannabis online from one of their most trusted sources: the pharmacy, rendering the therapeutic drug more accessible than ever before. Ordering medical cannabis from a familiar source may be less intimidating — and more convenient — to some patients than a visit to their local recreational weed dispensary, and purchasing medication online from a reputable pharmacy can help reinforce patients’ peace of mind (and provide more treatment options) in a way that ordering directly from a single licensed producer simply can’t match.

However, a common issue that often arises with medical cannabis is that pharmacists responsible for prescribing medicine for patients are accustomed to dispensing medications with a standardized level of active ingredients, and thus are reluctant to contend with the variability that can occur when dispensing plant-based treatments such as the cannabis flower.

The potential for inconsistency, paired with the lack of a comprehensive, central source of information that details the particular qualities of a specific product or cultivar, can make dispensing cannabis a daunting task. In light of medical cannabis dispensation by pharmacies being in its nascent stages, pharmacists, patients, and caregivers alike may not feel fully confident in selecting from the plethora of cannabis products available to them — never mind the correct dose, frequency, and ideal method of consumption.

Enter blockchain.

Whether dried flower, extracts, topicals, or edibles, blockchain tech allows patients and healthcare professionals to access vital information about cannabis products such as the level of major cannabinoids such as THC (aka tetrahydrocannabinol, the intoxicating compound in the cannabis plant) and CBD (aka cannabidiol, a psychoactive, but non-intoxicating compound found in cannabis), as well as minor cannabinoids and terpenes (organic aromatic compounds secreted in the plant’s glands, which are speculated to affect the properties of cannabis due to the entourage effect).

Managing critical quality data on cannabis products, such as detailed analytical test details, as well as genetics, metabolomics, and other critical manufacturing information documents, is essential to standardizing quality. Furthermore, by collecting and storing this information on a blockchain database, it can create the foundation for a more accurate, scientifically-backed method of tracking cannabis-based treatments that more closely resembles one expected of any other pharmaceuticals.

But the benefits of blockchain tech aren’t limited to measuring and tracking levels of THC and CBD.

Blockchain can also help advisors and healthcare professionals assess consistency from batch to batch and inform patients of any potential variations in their meds, which is crucial information when determining the correct dose and product in a sea of cultivars and consumption options.

Blockchain can also help pharmacists who are unfamiliar with cannabis guide patients towards the cultivars (known colloquially as “strains”) that are most suited for the patient’s specific needs, including both the specific interactions of the drug and the drug’s contraindications (the impact on the patient’s other medications).

Pharmacies are uniquely positioned in that they can dispense cannabis to patients via online channels while simultaneously being acquainted with their medical histories and any other medications they may be prescribed or purchasing over-the-counter. Armed with that patient familiarity and a tried-and-tested source of information, sourcing medical cannabis from pharmacies can help ensure a safe experience with limited side effects and without contraindications — while maximizing the efficacy of the treatment.

The immutability and rapid access to data provided by blockchain can be an indispensable tool. Blockchain helps patients successfully treat their symptoms with the added peace of mind that comes with obtaining their medication, be it pill or plant, under the banner of a trusted pharmacy. Implementing this technology in a pharmacy setting can empower patients to be confident about the safety, consistency, and reliability of the medical cannabis product, and it can enable pharmacies to remain on the cutting edge of patient care while dispensing safe and effective treatment options tailored to each individual.

Robert Galarza is Chief Executive Officer of TruTrace Technologies, developer of the first integrated blockchain platform that registers and tracks intellectual property from Genome to Sale for the cannabis industry.

Technical420: MediPharm Labs Selected for First Real-World Evidence, Patient-Centred Clinical Trial Using Blockchain Technology

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced its participation in a ground-breaking collaboration between University Health Network and Medical Cannabis by Shoppers Inc. that will use blockchain technology to track medical cannabis products from seed to sale….

The collaboration will use a blockchain-secured software platform – designed by TruTrace Technologies Inc. (CSE: TTT)(OTCQB: TTTSF) (CSE: TTT)(OTCQB: TTTSF) and integrated with the Medical Cannabis by Shoppers portal – to manage, track and trace medical cannabis strains in 7 distinct products manufactured by MediPharm Labs, or about 20% of the study formulary, in various formats including oils and extracts throughout each step of the supply chain.

Robert Galarza, CEO, TruTrace Technologies commented, “The evolution of the medical cannabis industry over the past several years has been nothing short of remarkable and the commitment by MediPharm Labs to implement the highest level of product quality through certified GMP standards and protocols, as well as a desire to advance innovation, collaboration and technology alongside companies like ours will only further drive our industry forward. We are excited to explore how the power of dynamic and transparent data can support their initiatives in Canada and beyond.”

“This important study, conducted by one of the largest  health research organizations in Canada, will have wide-reaching benefits for cannabis patients and MediPharm Labs as we remain dedicated to producing pharmaceutical-quality products that are rigorously tested and verified on a lot-by-lot basis using GMP certified standards,” said Pat McCutcheon, Chief Executive Officer, MediPharm Labs. “Our view is that this study has the potential to enhance confidence in medical cannabis by giving physicians and patients true transparency into product chemistry, composition and effectiveness so that they can prescribe validated products and adjust their treatment regimens based on real-world evidence. We are proud to be a contributing partner with leaders in the fields of science, technology, medical dispensary and cannabis who have come together to make this study possible.”…

Shoppers Drug Mart and TruTrace add data insights to help doctors

TruTrace Technologies (CSE: TTT-OTCQB: TTTSF) CEO Robert Galarza joined Steve Darling from Proactive Vancouver with news the their partner company Shoppers Drug mart is now looking to increase available data from its online medical cannabis marketplace to try and allow doctors to access more data.

Galarza discusses that data and how that is a way to allow doctors more data so they can feel more comfortable prescribing the drug to their patients.

Shoppers Drug Mart to grow medical pot sales with data

Shoppers Drug Mart is adding more robust data to its online medical cannabis marketplace to help doctors get comfortable prescribing the drug.

The Loblaw-owned (L.TO) pharmacy chain launched its Medical Cannabis by Shoppers Drug Mart digital portal nationwide last December. Unlike recreational pot, medical cannabis is exclusively sold online. Shoppers Drug Mart offers products from a dozen licenced producers through its pot website.

Ken Weisbrod, the company’s vice president of business development, and a pharmacist by trade, sees better data as key to gaining the trust of doctors wary of prescribing cannabis, due to the unknowns compared to conventional pharmaceuticals with Drug Identification Numbers. 

“Cannabis is a combination of many different molecules in the plant, so doctors have to get their head around that,” he told Yahoo Finance Canada on Wednesday. “What we want to do for them is provide them with a much more robust look at the products that we offer.”

Shoppers is launching a new online portal for doctors on Thursday as part of a study led by the University Health Network aimed at matching patients with the right cannabis products. It will include detailed cannabinoid and terpene information designed to help medical professionals better understand the properties of pot strains.

Weisbrod said the process can be more complicated than simply determining the right product. Since licenced producers often source cannabis through third-party wholesale agreements, there can be variations from batch to batch. That’s a problem for doctors who demand consistency.

“There have been some patients who start therapy on cannabis, and it’s doing wonders for them. Then it doesn’t work in a couple of months. Part of that reason is, it might not necessarily be the same product that they were originally on,” he said. “That really isn’t the way of medicine.”

Last June, Shoppers announced a partnership with blockchain company TruTrace Technologies (TTT.CN) to oversee product consistency, quality and genetics throughout the supply chain from genome-to-patient with the goal of bringing medical cannabis closer in line with standards for other drugs.

“In Canada, we have roughly 85,000 physicians. Really a small cohort, less than 10 per cent, have really embraced cannabis,” Weisbrod said. “Having a change in the way physicians prescribe takes years. It doesn’t happen overnight.”

Toronto-based Auxly Cannabis Group (XLY.V) sells to medical users through the Shoppers portal. Chief executive officer Hugo Alves said the additional data showcases his company’s testing and quality assurance measures for the doctors writing prescriptions.

“Now that science, innovation, and importantly research are becoming a more prevalent part of cannabis as a medicine, a trend that you will see is an absolute demand for increasing rigour in consistency and accuracy,” he said in an interview. “It’s raising the bar on standards throughout the entire industry.”

Weisbrod said Shoppers Drug Mart remains focused on the medical side of the cannabis business, and does not intend to pursue recreational sales. He declined to comment on the size of the company’s share of the Canadian medical market. 

As for next steps, Weisbrod hopes regulatory changes will soon allow medical cannabis to be offered in the company’s physical pharmacies.

“In 2022, they’ll look into the medical regime, and maybe they’ll open it up and put it in pharmacies,” he said. “Our hope is for patients to walk in and get cannabis like their other medications.”

Jeff Lagerquist is a senior reporter at Yahoo Finance Canada. Follow him on Twitter @jefflagerquist.

Medical Cannabis put to the test in first ever real-world evidence clinical trial led by UHN

Newswise — (Toronto – July 9, 2020) – Medical cannabis is finally being put under the microscope, in a first-of-its-kind real world evidence study led by Dr. Hance Clarke, Director of Pain Services, Toronto General Hospital, and a recognized leader in educating Canadians about chronic pain management and the risk factors of continued opioid use. 

The Medical Cannabis Real-World Evidence (MC-RWE) clinical trial will allow patients to select medical cannabis products that are tested, from seed straight through to packaging. Patients using the online portal created by Medical Cannabis by Shoppers, will know exactly what is in their product: how many milligrams of THC and cannabidiol are being consumed, and if it works for them, they can rely on the product being exactly the same, from batch to batch. 

“The challenge with the medical use of cannabis is that physicians and patients are unsure of the quality of products being consumed,” says Dr. Clarke. “For the first time we will have a national repository of data that can provide answers about the effectiveness of these products, to test their claims.” 

Patients in the MC-RWE clinical trial will have access to a wide range of products including dried flower, oil extracts, edibles, and, topical preparations through the portal, which is the online platform for the sale of medical cannabis by Canadian retail pharmacy chain, Shoppers Drug Mart. 

In an industry where standardization is still in its infancy, this study aims to give direction with the same rigour around medical cannabis that is demanded of any other pharmaceutical product. 

“Medical Cannabis by Shoppers is best placed to offer Canadians the reassurance of medical products that have been tested and validated,” says Ken Weisbrod, Vice President, Business Development/Cannabis Strategy, Shoppers Drug Mart. “Our development of a blockchain secured initiative, with TruTrace Technologies Inc., has now been integrated into an operational portal that will provide products with an immutable digital identity, that can capture everything from detailed chemistry down to its DNA.” 

Users of medical cannabis have long been vocal about its efficacy in treating chronic pain. Cannabis has also been championed as an alternative to opioids in the treatment of chronic pain. With anecdotal testimonies in abundance, Dr. Clarke, a key opinion leader in the pain management arena, knows that scientific data is necessary to help patients access alternative pain relief and test these assertions.    

“We need the evidence to help us in prescribing the appropriate validated product, at the right dose, for the right patient,” says Dr. Clarke. “Ensuring quality standards will allow physicians and their patients to be confident about using medical cannabis to treat a wide range of pain-related ailments.”

Dr. Clarke is a staff anesthesiologist, Director, Pain Services, Medical Director of The Pain Research Unit, and, Director of the Good Hope Ehlers Danlos Clinic, UHN.


Contacts for HCPs:

  1. For more information, go to the RWE website:
  2. Contact the study coordinator or PI at 416-340-4800 x4251 or email at
  3. If you’re ready to sign on to the e-portal as a recruiting physician go to


Contact for Patients:

  1. For more information please speak to your  doctor to learn if you are eligible to participate or visit 



About University Health Network

University Health Network consists of Toronto General Hospital, recently ranked the #4 Hospital in the World according to Newsweek Magazine, and Toronto Western Hospital, the Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, and the Michener Institute of Education at UHN. The scope of research and complexity of cases at University Health Network has made it a national and international source of discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. University Health Network is a research hospital affiliated with the University of Toronto.

Proactive: TruTrace Sees Strong Adoption with Producers

“Over 10 major producers have flocked to the StrainSecure platform to track strains of medical cannabis and verify their authenticity

The company’s StrainSecure track and trace platform provides mandatory testing, DNA-based product validation, and helps with intellectual property protection and product guarantees for patients and customers.

The Vancouver-based firm channels the power of blockchain to fix the grim realities of corrupted supply chains in the medical cannabis industry. It combines the power of big data with the security of blockchain to provide strain identification, registration and verification for cannabis at scale.

The firm’s immutable, cryptographically secure technology is the brainchild of co-founder and chief technology officer Tommy Stephenson, who developed enterprise software platforms over two decades for companies such as Microsoft and Mercedes Benz. The company’s Seattle development center has “a Disney feel” to it with the engineers exuding an “if we can dream it, we can build it” philosophy.

The Seattle team’s goal has been to build a framework to help licensed cannabis producers and micro-cultivators easily and inexpensively move their products through the mandatory testing process. TruTrace places that test data on the blockchain for its own protection and that of the company’s intellectual property.

In this way, the StrainSecure platform establishes an accurate, single source, validated, and permanent account for cannabis strains from seed source to market. A cannabis strain’s genetics are stored into an immutable ledger and information is added during each processing stage.

In short, TruTrace’s seed-to-sale tracking platform tackles two pain points in the cannabis industry: it modernizes the inventory tracking system and provides customers with details about a product’s lab test results and cultivar….”

Find out more read the full article by clicking on the button below.  

Proactive: TruTrace Technologies Strikes License Deal with Logistics Group OrionOne

“TruTrace Technologies Inc (CSE:TTT) (OTCMKTS:TTTSF), the cannabis-focused blockchain group, has struck a software license deal with logistics group OrionOne Global Inc, which will allow it to widen its client base, the firm said.

OrionOne is a global supply chain provider which has developed a logistics and tracking smart-hub for navigating shipments and logistics.

TruTrace said the deal would allow it to leverage the OrionOne platform to support commercialization of its core products for its customers.

It not only assures the long-term functionality of StrainSecure(TM), but “we believe it will open up market opportunities for TruTrace in other key industries”, Robert Galarza, CEO of TruTrace, told investors in a statement.

“Our core mission was built on traceability of quality assurance and testing details at a very granular level and we believe the incorporation of logistics tracking will significantly expand our client base.”

TruTrace’s platform has been designed to power the traceability of testing standards within the legal cannabis, nutraceutical, food and pharma industries.

“Licensing OrionOne will give TruTrace the ability to maximize its commercial opportunities, as well as begin to expand its offering beyond the cannabis industry,” Tommy Stephenson, the founder and CEO of OrionOne noted.

He said when the firm developed OrionOne over four years ago it was with a macro view of shipping and logistics, which will complement the precise level of detail provided by TruTrace…”

Find out more read the full article by clicking on the button below.